Registration to this Virtual Event is free of charge and gives you 180 days access. You will be sent details of how to access the event via email after registration.
For more information please click here.
 | Beyond Genomics For Personalized Medicine
Sam Hanash, University of Texas MD Anderson Cancer Center
Advances in technology for cancer molecular profiling at the proteomic, immunomic and metabolomic levels provide opportunities for personalized treatment beyond tumor genomic profiling and for tailoring treatment based on expression of therapeutic targets and tumor microenvironment profiles.
| |
 | Dealmaking in the Personalized Medicine space: Recent Trends and Forward Prospects
Ryan Richardson, J.P. Morgan
| |
 | Detection, Characterization and ex vivo Expansion of Viable CTCs
Catherine Alix-Panabieres, University Medical Center of Montpellier
We describe, for the first time, the establishment of a permanent cell line from CTCs of one colon cancer patient. It allows a wealth of functional studies on the biology of CTCs as well as in vitro and in vivo drug testing.
| |
| Detection, Characterization and ex vivo Expansion of Viable CTCs
Catherine Alix-Panabières, University Medical Centre of Montpellier
We describe, for the first time, the establishment of a permanent cell line from CTCs of one colon cancer patient. It allows a wealth of functional studies on the biology of CTCs as well as in vitro and in vivo drug testing.
| |
 | Developing Personalized Medicine in Oncology
Christof von Kalle, German Cancer Research Center
The Precision Oncology Program (NCT POP) at the National Center for Tumor Diseases – (NCT) Heidelberg focuses all translational activities and resources towards individualized cancer medicine, including patient-oriented strategies in genomics, proteomics, immunology, radiooncology, prevention, and early clinical development.
| |
 | Early Engagement with Health Technology Assessment: Its Role in Evidence Generation
Ailish Higgins, National Institute for Health and Care Excellence (NICE)
Early engagement with payers and health technology assessment (HTA) bodies can help to identify key clinical and economic issues in a product’s development. Thinking about solutions to these issues as early as possible can avoid unnecessary delays and inefficiencies on the road to reimbursement.
| |
 | From Sequencing To Interpretation: Bioinformatics Challenges In Next Generation Sequencing Cancer Diagnostics
Jeremy Segal, University of Chicago
Clinical laboratories aiming to establish next generation sequencing (NGS) oncology diagnostics face a daunting array of bioinformatics challenges. This lecture will review some of the major challenges at different phases of the process, from the development of NGS analysis pipelines for detection of neoplastic genomic anomalies to the implementation of systems to support clinical interpretation.
| |
 | Liquid Biopsy: Detection and molecular characterization of circulating tumor cells and DNA
Klaus Pantel, University Medical Center Hamburg-Eppendorf
The analysis of CTCs, ctDNA and circulating microRNAs may provide complementary information as “liquid biopsy”. This information can be used as companion diagnostics to improve the stratification of therapies and to obtain insights into therapy-induced selection of cancer cells.
| |
 | Oncology and beyond : PHC approaches and the benefit to patients / healthcare
Jean-Jacques Palombo, Roche
Jean-Jacques Palombo, SVP Cardiac, Women’s Health Companion Diagnostics (CDx) will highlight why PHC is central to Roche’s strategy, how Roche makes PHC happen and how this concept is also being applied to high areas of unmet need beyond Oncology, such as Alzheimer’s Disease.
| |
 | Predicting the Predictiveness: Preclinical-to-clinical Bridging of Personalized Therapies using Translational Modeling
Arijit Chakravarty, Takeda Pharmaceuticals Co Ltd
| |
 | The Network Genomic Medicine: Providing Structures for Personalised Cancer Therapies
Reinhard Buettner, University Hospital Cologne
The Network Genomic Medicine has been established in 2010 for centralized genomic profiling of malignant tumors. In parallel a platform for innovative clinical studies has been implemented as a key element for Personalised Cancer Medicine.
| |
 | Translating Pharmacogenomics into the Clinic: A Regulatory Perspective
Theodora Katsila, University of Patras
The lecture will revolve around the regulatory issues and challenges to translate pharmacogenomics research findings into clinical applications to individualize drug treatment.
| |
Back to the top
|
